Home
/
Theravance Biopharma, Inc.
/
Financials
/
Quarterly
Theravance Biopharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Theravance Biopharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$8.32M
May 9, 2018
Q3
2017
Sep 30, 2017
$4.28M
Nov 8, 2017
Q2
2017
Jun 30, 2017
$3.51M
Aug 9, 2017
Q1
2018
Mar 31, 2017
$3.09M
May 9, 2018
Q3
2017
Sep 30, 2016
$19.08M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$5.47M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$18.41M
May 10, 2017
Q3
2016
Sep 30, 2015
$10.70M
Nov 9, 2016
Q2
2016
Jun 30, 2015
$7.13M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$20.40M
May 10, 2016
Q3
2015
Sep 30, 2014
$6.34M
Nov 12, 2015
Q2
2015
Jun 30, 2014
$2.97M
Aug 13, 2015
Q1
2015
Mar 31, 2014
$945.0K
May 13, 2015
Q3
2014
Sep 30, 2013
$24.0K
Nov 12, 2014
Q2
2014
Jun 30, 2013
$5.0K
Aug 14, 2014
Q1
2014
Mar 31, 2013
$22.0K
Jun 24, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$19.99M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$26.20M
Aug 13, 2025
Q1
2025
Mar 31, 2025
$15.39M
May 12, 2025
Q3
2025
Sep 30, 2024
$16.87M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$14.26M
Aug 13, 2025
Q1
2025
Mar 31, 2024
$14.50M
May 12, 2025
Q3
2024
Sep 30, 2023
$15.69M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$13.75M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$10.42M
May 15, 2024
Q3
2023
Sep 30, 2022
$12.45M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$11.05M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$13.20M
May 10, 2023
Q3
2022
Sep 30, 2021
$13.19M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$12.91M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$14.26M
May 6, 2022
Q3
2021
Sep 30, 2020
$18.26M
Nov 8, 2021
Q2
2021
Jun 30, 2020
$15.01M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$19.86M
May 6, 2021
Q3
2020
Sep 30, 2019
$12.43M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$26.15M
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$3.62M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$54.84M
Aug 13, 2025
Q1
2025
Mar 31, 2025
($13.58M)
May 12, 2025
Q3
2025
Sep 30, 2024
($12.70M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($16.53M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($11.66M)
May 12, 2025
Q3
2024
Sep 30, 2023
($8.95M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($15.65M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($22.09M)
May 15, 2024
Q3
2023
Sep 30, 2022
$916.63M
Nov 9, 2023
Q2
2023
Jun 30, 2022
($8.19M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($25.95M)
May 10, 2023
Q3
2022
Sep 30, 2021
($35.31M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($52.41M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($79.68M)
May 6, 2022
Q3
2021
Sep 30, 2020
($73.64M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($62.89M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($83.05M)
May 6, 2021
Q3
2020
Sep 30, 2019
($58.43M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($39.84M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($6.46M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($2.73M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($14.43M)
May 12, 2025
Q3
2025
Sep 30, 2024
($10.84M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($15.71M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($11.21M)
May 12, 2025
Q3
2024
Sep 30, 2023
($8.76M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($16.12M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($24.91M)
May 15, 2024
Q3
2023
Sep 30, 2022
($14.20M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($23.10M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($37.22M)
May 10, 2023
Q3
2022
Sep 30, 2021
($53.62M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($64.11M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($83.89M)
May 6, 2022
Q3
2021
Sep 30, 2020
($76.62M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($72.18M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($72.48M)
May 6, 2021
Q3
2020
Sep 30, 2019
($65.20M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($42.48M)
Aug 10, 2020